Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators will use P-HDFL, a regimen with high tumor remission rate (~
60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for
patients with non-resectable gastric cancer. For those patients who have achieved complete
response (CR) or partial response (PR), DI will be used to "consolidate" the remission. For
those patients who fail to achieve remission by P-HDFL, DI will be used as salvage
chemotherapy. The efficacy and toxicities of DI in these two settings will be evaluated in
this prospective study.